<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Adiponectin is an adipocyte-derived hormone that plays a critical role in the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> via interaction with adiponectin receptors 1 (ADIPOR1) and 2 (ADIPOR2) </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> is a peroxisome proliferator-activated receptor-gamma (PPARG) <z:chebi fb="4" ids="48705">agonist</z:chebi> that is widely used in the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesised that <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> regulates <z:chebi fb="23" ids="18059">lipid</z:chebi> and <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism through modulation of the expression of adiponectin receptors in the liver </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The expression of ADIPOR1 and ADIPOR2 was analysed in HepG2 hepatocytes </plain></SENT>
<SENT sid="4" pm="."><plain>The promoters of adiponectin receptors were isolated and used to analyse the transcriptional regulation </plain></SENT>
<SENT sid="5" pm="."><plain>The expression of adiponectin receptors in the liver was determined in mice treated with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> elevated the <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels of ADIPOR2 and stimulated ADIPOR2 promoter in HepG2 cells </plain></SENT>
<SENT sid="7" pm="."><plain>Analysis with the ADIPOR2 promoter revealed a putative <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>-responsive region that contained a <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> receptor (GR)-binding element </plain></SENT>
<SENT sid="8" pm="."><plain>The GR <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> synergised with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> to stimulate the ADIPOR2 promoter wheras the GR <z:chebi fb="68" ids="48706">antagonist</z:chebi> RU486 abolished this stimulation </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment of mice with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> elevated the expression of ADIPOR2 in the liver </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: This study indicates that <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> can elevate the expression of ADIPOR2 in hepatocytes </plain></SENT>
<SENT sid="11" pm="."><plain>Our data also suggest that the PPARG <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> can interact functionally with a GR element in the ADIPOR2 promoter to mediate stimulation of transcription </plain></SENT>
<SENT sid="12" pm="."><plain>This study thus reveals a new paradigm underlying the therapeutic effect of PPARG activators in the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>